Form 4: AngioDynamics Director Jan Reed Receives Annual Stock Compensation
Insider Transaction Report
AngioDynamics Inc. Director Jan S. Reed acquired 17,675 shares of common stock as part of her regular annual compensation, immediately vesting upon grant.
Summary
- Jan S. Reed, a Director of AngioDynamics Inc. (ANGO), acquired 17,675 shares of common stock on July 16, 2025.
- The acquisition represents restricted stock units granted as regular annual compensation for her service as a director.
- The restricted stock units vested immediately at the time of grant, with a transaction price of $0 per share.
- Following this transaction, Jan S. Reed beneficially owns a total of 105,034 shares of AngioDynamics common stock.
- A Substitute Power of Attorney was executed on January 20, 2025, appointing Lawrence T. Weiss as a substitute attorney-in-fact for Jan S. Reed, replacing Stephen A. Trowbridge, for the purpose of executing SEC Forms 3, 4, and 5.
Sentiment
Score: 7
Explanation: The sentiment is positive as a director received stock compensation that immediately vested, aligning their interests with shareholders. This is a routine and expected event for director remuneration.
Positives
- The acquisition of shares by a director aligns their interests with those of shareholders.
- The immediate vesting of the restricted stock units indicates a direct and immediate increase in the director's ownership stake.
Future Outlook
No forward-looking statements or guidance are provided in this filing, as it primarily reports an insider transaction.
Industry Context
This filing details a routine insider compensation event, which is a common practice across industries to incentivize and align the interests of directors with company performance and shareholder value. It does not provide broader industry trends or competitive insights.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Change | Stephen A. Trowbridge, the previous attorney-in-fact for Jan S. Reed, appointed Lawrence T. Weiss as a substitute attorney-in-fact for the purpose of executing SEC Forms 3, 4, and 5 on behalf of Jan S. Reed. | 01/20/2025 | This administrative change streamlines the process for the director's SEC filings, ensuring continuity in compliance. |
Stakeholder Impact
- Shareholders: The director's increased ownership stake through compensation aligns their interests with shareholder value creation.
Key Dates
| Date | Description |
|---|---|
| 01/20/2025 | Execution date of the Substitute Power of Attorney appointing Lawrence T. Weiss. |
| 07/16/2025 | Date of acquisition of 17,675 shares of common stock by Jan S. Reed. |
| 07/18/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
AngioDynamics, ANGO, Director Compensation, Restricted Stock Units, Insider Ownership, SEC Form 4, Stock Grant, Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.